Dr. Eric Topol

The trade-off here is something maybe not in the United States, Katie, but in most of the rich countries around the world, and an example would be the UK, but many others, they're going to be providing all these things because they're low cost to everyone because preventing these diseases and promoting health of the population is what we want to do, right?

Of course.

We have this crazy system here, which is, you know, out of pocket and poor insurance coverage and inaccessibility.

We're not positioned well to implement this new era of prevention, but other countries will.

Yeah, that's kind of why I wrote the book, Katie, because the people should know about this stuff.

I mean, there's a revolution going on and it's very quiet.

You know, nobody's heard of organ clocks, you know, or PTAL 217 or, you know, a lot of things that we're talking about, how inexpensive it is to get polygenic risk scores for all these conditions or even a genome sequence.

So most doctors are unaware.

Maybe with AI, they'll be more aware as we go forward.

But we have a void of knowledge in the medical community.

And it's because everyone's busy and they just can't keep up with these.

You know, these are big discoveries that are being made.

Yeah, yeah, yeah.

But you nailed it, which when why aren't we doing this?

We should be investing in this, not gutting the resources, because we've never had such a propitious time in medicine to change the whole arc of these big diseases, which, you know, by 65, the majority of Americans have at least one of these diseases.

And it's just the elderly.

We have to flip the elderly to the elderly and we can do it.

One last point is you don't have to do any of these tests if you do all the lifestyle factors.

If you do that.

The reason to do these tests is to motivate you to do the lifestyle factors.